Supreme Court Leaves Abortion Pill Telehealth System Untouched

The Supreme Court refused Wednesday to block telehealth prescriptions and mail delivery of abortion pills, leaving intact a system that has quietly become the most common method of ending pregnancies in America.

The justices declined to hear a challenge from three states seeking to restrict mifepristone access through telemedicine. The unsigned order means women can continue obtaining the two-drug regimen through virtual doctor visits, with pills shipped directly to their homes.

More than half of U.S. abortions now happen this way. The FDA permanently authorized telehealth prescribing in 2021, and the practice expanded dramatically after the Court overturned Roe v. Wade in 2022. Women in states with abortion bans have used the system to receive pills from providers in shield states that protect prescribers from prosecution.

Three Republican-led states — Idaho, Kansas, and Missouri — asked the Court to intervene, arguing the telehealth system undermines their ability to enforce state abortion laws. Their attorneys pointed to cases where women in restrictive states obtained pills through out-of-state prescribers operating online.

The states also raised safety concerns, claiming the remote prescription model prevents proper screening for ectopic pregnancies and other complications. Medical groups disputed this, noting medication abortion has been studied for decades and carries lower complication rates than Tylenol or penicillin.

The Court’s decision not to take the case leaves federal approval of mifepristone unchanged. But the fight over abortion pills is far from over. At least eight states have passed laws attempting to criminalize mailing abortion pills across state lines, and several ongoing cases challenge whether states can prosecute out-of-state providers.

Legal experts say the issue hinges on conflicts between state authority and federal drug regulation. The FDA maintains exclusive power to approve medications for interstate commerce, but states claim traditional police powers to regulate medical practice within their borders.

The pharmaceutical industry watched closely. Any Court ruling limiting telehealth prescribing could have rippled through other areas of telemedicine that exploded during the pandemic — from psychiatric care to chronic disease management to erectile dysfunction drugs.

Justice Clarence Thomas dissented from the order without explanation, though he has previously questioned whether the FDA properly evaluated mifepristone’s risks when it first approved the drug in 2000.

The case follows last year’s Supreme Court decision dismissing a separate challenge to mifepristone on procedural grounds. In that ruling, the Court said anti-abortion doctors lacked standing to sue because they couldn’t prove they were harmed by the drug’s availability.

Wednesday’s order means the legal battle moves back to lower courts and state legislatures, where battles over enforcement and jurisdiction will continue.